BIO Elects New Officers, Welcomes 10 New Board Members
ATLANTA, GA (May 18, 2009) – The Board of Directors of the Biotechnology Industry Organization today elected a new slate of officers and 10 new board members at its meeting at BIO’s 2009 Annual Convention.
“We are honored to have some of the industry’s best thinkers working closely with our membership and senior staff,” said BIO President and CEO Jim Greenwood. “Each of these individuals brings exceptional perspective, insight, and experience that will contribute to the health and growth of the industry, as well as the judicious oversight of BIO as a membership organization.”
The members of the Executive Committee of BIO’s Board of Directors are:
Stephen A. Sherwin, MD, Board Chair*
CEO, Cell Genesys, Inc.
Mark Skaletsky, Treasurer*
President & CEO, Fenway Pharmaceuticals
Fabrizio Bonanni, Secretary*
EVP, Operations, Amgen
Joshua Boger, PhD, Immediate Past Chair
CEO, Vertex Pharmaceuticals, Inc.
Rachel King, Chair for Emerging Companies*
CEO, Glycomimetics
Ron Cohen, Vice Chair for Emerging Companies
President & CEO, Acorda Therapeutics
Joachim Schneider, Chair for the Food & Ag Section*
Head of BioScience, Bayer CropScience
Barbara Wells, PhD, Vice Chair for the Food & Ag Section
President & CEO, ArborGen, LLC
Tom Watkins, Vice Chair for the Health Section*
CEO, Human Genome Sciences
Alan Shaw, Chair for the Industrial & Environmental Section*
CEO, Codexis
Tjerk de Ruiter, Vice Chair for the Industrial & Environmental Section
CEO, Genencor
Ian T. Clark, At Large
Head of Global Product Strategy & Chief Marketing Officer, Roche Pharma Division
Douglas A. Doerfler, At Large
President & CEO, Maxcyte, Inc.
Paul Hastings, At Large
President & CEO, Oncomed Pharmaceuticals, Inc.
James C. Mullen, At Large
President & CEO, Biogen Idec, Inc.
Richard F. Pops, At Large
Chairman, Alkermes, Inc.
David E. I. Pyott, At Large
Chairman & CEO, Allergan
Henri A. Termeer, At Large
Chairman, President & CEO, Genzyme Corporation.
*also serves as an Officer of the Board of Directors
BIO’s Board of Directors is composed of members of the Governing Boards for each of BIO’s four sections: Health, Emerging Companies, Industrial & Environmental and Food & Agriculture. The new members of BIO’s Board of Directors are:
Ian T. Clark, Head of Global Product Strategy & Chief Marketing Officer, Roche Pharma Division
(also of BIO’s Health Governing Board)
Peter Eckes, CEO & Managing Director, BASF Plant Science
(also of BIO’s Food & Agriculture Governing Board)
Sue Ellerbusch, President, BP Biofuels North America
(also of BIO’s Industrial & Environmental Governing Board)
Stephen J. Gatto, Chairman & CEO, Bioenergy International, LLC
(also of BIO’s Industrial & Environmental Governing Board)
Perry Karsen, Chief Executive Officer, Pearl Therapeutics
(also of BIO’s Emerging Companies Governing Board)
Daphne Preuss, Chief Executive Officer, Chromatin, Inc.
(also of BIO’s Food & Agriculture Governing Board)
Arthur Sands, MD, PhD, President & CEO, Lexicon Genetics Incorporated
(also of BIO’s Emerging Companies Governing Board)
Ron Stotish, Chief Executive Officer, Aqua Bounty Technologies
(also of BIO’s Food & Agriculture Governing Board)
Ellen Strahlman, MD, Senior Vice President & Chief Medical Officer, GlaxoSmithKline, PLC
(also of BIO’s Health Section Governing Board)
Mark Wong, Chief Executive Officer, Agrivida
(also of BIO’s Food & Agriculture Governing Board)
# # #
Upcoming BIO Events
BioEquity Europe
June 9-10, 2009
Munich, Germany
World Congress on Industrial Biotechnology & Bioprocessing
July 19-22, 2009
Montreal, Quebec, Canada
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
###